Arcutis Biotherapeutics, Inc. (ARQT) key performance indicators and operating metrics (13 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| ZORYVE Net Product Revenue | 105.4M | FY2026-Q1 |
| Selling, General and Administrative Expenses | 74.08M | FY2026-Q1 |
| Research and Development Expenses | 30.63M | FY2026-Q1 |
| Cost of Sales | 9.78M | FY2026-Q1 |
| Loss from Operations (GAAP) | -9.09M | FY2026-Q1 |
| Total Product Revenues | 81.5M | FY2025-Q2 |
| Total Operating Expense | 96.1M | FY2025-Q2 |
| Weighted average shares outstanding(million) | 127.00 | FY2025-Q2 |
| Total debt, net (Sep. 30, 2024)1 | 108M | FY2025-Q2 |
| Weekly TRX (rolling 4-week basis) | 16.5K | FY2025-Q2 |
| Prescriptions Covered by Insurance | 80.00 percent | FY2025-Q2 |
| Zoryve Cream 0.3% Unique Prescribers (Since Launch) | 18K | FY2025-Q1 |
| Zoryve Cream 0.3% Prescriptions Filled (Since Launch) | 425K | FY2025-Q1 |
Back to ARQT overview · ARQT earnings · ARQT holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.